MEDNAX Sees Unusually High Options Volume (MD)

MEDNAX Inc (NYSE:MD) was the target of some unusual options trading activity on Thursday. Stock investors purchased 857 put options on the company. This represents an increase of approximately 1,058% compared to the average volume of 74 put options.

Shares of MEDNAX (NYSE MD) opened at $53.52 on Tuesday. The company has a market cap of $5,010.00, a PE ratio of 18.98, a PEG ratio of 1.69 and a beta of 0.40. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. MEDNAX has a 12-month low of $40.56 and a 12-month high of $72.13.

MEDNAX (NYSE:MD) last issued its earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.87. The business had revenue of $868.95 million during the quarter, compared to analysts’ expectations of $864.78 million. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.09 earnings per share. sell-side analysts anticipate that MEDNAX will post 3.1 EPS for the current fiscal year.

In other news, Director Cesar L. Alvarez sold 10,668 shares of the company’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total value of $454,350.12. Following the sale, the director now directly owns 44,215 shares of the company’s stock, valued at approximately $1,883,116.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares in the company, valued at $1,834,649.02. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. boosted its stake in MEDNAX by 5.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 295,514 shares of the company’s stock worth $17,841,000 after buying an additional 15,715 shares during the period. SG Americas Securities LLC boosted its stake in MEDNAX by 125.2% during the second quarter. SG Americas Securities LLC now owns 42,635 shares of the company’s stock worth $2,574,000 after buying an additional 23,706 shares during the period. Bank of New York Mellon Corp boosted its stake in MEDNAX by 7.4% during the second quarter. Bank of New York Mellon Corp now owns 1,304,975 shares of the company’s stock worth $78,782,000 after buying an additional 90,002 shares during the period. Legal & General Group Plc boosted its stake in MEDNAX by 14.6% during the second quarter. Legal & General Group Plc now owns 156,414 shares of the company’s stock worth $9,443,000 after buying an additional 19,869 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its stake in MEDNAX by 115.8% during the second quarter. BNP Paribas Arbitrage SA now owns 52,850 shares of the company’s stock worth $3,191,000 after buying an additional 28,359 shares during the period. Hedge funds and other institutional investors own 98.43% of the company’s stock.

A number of analysts recently issued reports on MD shares. KeyCorp set a $51.00 price target on shares of MEDNAX and gave the stock a “buy” rating in a report on Wednesday, November 1st. SunTrust Banks set a $55.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a report on Thursday, December 21st. Jefferies Group reissued a “hold” rating and set a $44.00 price target on shares of MEDNAX in a report on Friday, November 3rd. Robert W. Baird reissued a “hold” rating and set a $47.00 price target on shares of MEDNAX in a report on Sunday, September 3rd. Finally, Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $53.82.

ILLEGAL ACTIVITY NOTICE: “MEDNAX Sees Unusually High Options Volume (MD)” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/26/mednax-sees-unusually-high-options-volume-md.html.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit